A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Summary

The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children. At first, only teenagers who meet the study rules can participate in this study. Children may only start to participate once enough information has been collected from other studies with zasocitinib.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Plaque Psoriasis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

4 to 17 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Takeda

Last updated on ClinicalTrials.gov

September 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites